-
Thematic Analysis
FDI Trends in North America (2025)
Canada’s FDI outlook remains rife with economic uncertainty, being intrinsically linked to the US. According to GlobalData’s FDI Database, the US constitutes approximately 45% of the 371 (announced) FDI projects in Canada’s inward FDI pipeline (from 2023 to close of Q2 2025). Prime Minister Mark Carney initially adopted a tough rhetoric, indicating a desire to renegotiate the USCMA trading agreement. Though, the current state-of-play reads that Canada has filed a WTO dispute contesting US tariff obligations, while elevated 35% tariffs...
-
Sector Analysis
Exploring Ongoing Drug Shortages in the Current Geopolitical Climate
GlobalData has reviewed the current reported drug shortage landscape across 19 markets, including anayses by geography, drug type, therapeutic area and orphan drug status, and has considered common factors contributing to these shortages.
-
Product Insights
Pulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Pulmonary Tuberculosis- Global Clinical Trials Review, 2025" provides an overview of Pulmonary Tuberculosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Tuberculosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Acquired (Autoimmune) Hemolytic Anemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acquired (Autoimmune) Hemolytic Anemia- Global Clinical Trials Review, 2025" provides an overview of Acquired (Autoimmune) Hemolytic Anemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Acquired (Autoimmune) Hemolytic Anemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor...
-
Product Insights
Cystic Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Cystic Fibrosis- Global Clinical Trials Review, 2025" provides an overview of Cystic Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Intracranial Hemorrhage Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Intracranial Hemorrhage- Global Clinical Trials Review, 2025" provides an overview of Intracranial Hemorrhage Clinical trials scenario. This report provides top line data relating to the clinical trials on Intracranial Hemorrhage. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)- Global Clinical Trials Review, 2025" provides an overview of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across...
-
Product Insights
High-Grade Glioma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “High-Grade Glioma- Global Clinical Trials Review, 2025" provides an overview of High-Grade Glioma Clinical trials scenario. This report provides top line data relating to the clinical trials on High-Grade Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome- Global Clinical Trials Review, 2025" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Nordic Countries Lead the Way in Facilitating Reimbursement Access to Anti-Migraine CGRP Inhibitors
Migraine treatment has been shaken up by enhanced reimbursement access to novel CGRP inhibitors across the Nordic region.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.